Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.
See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.
Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.
Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.
Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

| TITLE/ COMPANY | Issue Date | Status | Details |
|---|---|---|---|
| OBJECTIVE 1b: A sound and appropriate program for sampling, testing, and evaluating components Not available |
29 Jun 2026 | Normal | Justification: The issue relates directly to the need for robust sampling methods and procedures to effectively evaluate material quality. Excerpt: Check the sampling plans to confirm that representative samples are collected and tested/examined to verify product quality. View Details |
| The responsibilities and procedures applicable to the quality control unit are not fully followed. Mylan Laboratories Limited |
15 May 2026 | Normal | Justification: The lack of testing details for individual samples indicates significant sample management oversights. Excerpt: Your worksheets had provision to record testing information for only sample out of samples. View Details |
| Other Comments - During our review, we noted multiple prescriptions filled April 14, 2025, to June 30, 2025, from the same prescriber at a county humane society for two different animals Mixlab WI LLC |
01 May 2026 | Normal | Justification: The observation indicates an issue related to mismanagement or misuse of prescribed medicinal samples, which falls under improper Sample Management practices. Excerpt: lack of patient-specific dosing instructions despite specific owner names being listed for both patients View Details |
| Donors were not screened by a review of relevant medical records for risk factors of communicable disease agents and diseases. Reproductive Sciences Medical Center |
08 Apr 2026 | Normal | Justification: Sample Management is linked as it involves oversight of potential donors being part of sample collection and eligibility verification. Excerpt: Donors were not fully screened by a review of relevant medical records for risk factors. View Details |
| Donors were not screened by a review of relevant medical records for risk factors of communicable disease agents and diseases. Reproductive Sciences Medical Center |
08 Apr 2026 | Normal | Justification: Sample Management is linked as it involves oversight of potential donors being part of sample collection and eligibility verification. Excerpt: Donors were not fully screened by a review of relevant medical records for risk factors. View Details |
View and learn more about FDA Inspections
with our comprehensive list of resources